# An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Participants With Euvolemic or Hypervolemic Hyponatremia

> **NCT02020278** · PHASE3 · TERMINATED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 3 (actual)

## Conditions studied

- Hyponatremia

## Interventions

- **DRUG:** Tolvaptan

## Key facts

- **NCT ID:** NCT02020278
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04-22
- **Primary completion:** 2017-10-23
- **Final completion:** 2017-10-23
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Issues with recruitment and enrollment made the trial impossible or highly impracticable. Termination of this trial was not due to safety reasons.
- **Last updated:** 2020-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02020278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02020278, "An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Participants With Euvolemic or Hypervolemic Hyponatremia". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02020278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*